The pace of T-cell research is matched only by the speed with which fundamental advances are being developed as new therapies. This report from a recent meeting updates developments in a number of immunointervention strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0167-5699(92)90146-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Checkpoint immunotherapy has made great strides in the treatment of solid tumors, but many patients do not respond to immune checkpoint inhibitors. Identification of tumor-infiltrating cytotoxic T cells (CTLs) has the potential to stratify patients and monitor immunotherapy responses. In this study, the design of cluster of differentiation (CD8) T cell-targeted nanoprobes that emit shortwave infrared (SWIR) light in the second tissue-transparent window for noninvasive, real-time imaging of CTLs in murine models of breast cancer is presented.
View Article and Find Full Text PDFIlluminating immunotherapy response via precision T cell-targeted PET imaging.
Front Med (Lausanne)
July 2024
Division of Molecular Imaging and Therapy, Oregon Health & Science University, Portland, OR, United States.
Traditionally, immunotherapy agent selection and treatment strategies are guided by biopsy-based histological information. However, biopsies are limited in that they are invasive, provide static information regarding the tumor immune microenvironment, and only sample a small part of one tumor site. The tumor microenvironment is dynamic and heterogenous.
View Article and Find Full Text PDFAdvancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.
EBioMedicine
August 2024
School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia; Graduate School of Biomedical Engineering, ARC Centre of Excellence in Nanoscale Biophotonics, Faculty of Engineering, UNSW Sydney, NSW 2052, Australia. Electronic address:
The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and high manufacturing cost associated with current ex vivo CAR T cell therapy products, alternative strategies to produce CAR T cells directly in the body have been developed in recent years. These strategies involve the direct infusion of CAR genes via engineered nanocarriers or viral vectors to generate CAR T cells in situ.
View Article and Find Full Text PDFNK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors.
Bladder Cancer
June 2023
The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: For decades, immunotherapies have been integral for the treatment and management of bladder cancer, with immune checkpoint inhibitors (ICIs) transforming patient care in recent years. However, response rates are poor to T cell-targeted ICIs such as programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) blocking antibodies, framing a critical need for complementary immunotherapies. Promising strategies involve harnessing the activation potential of natural killer (NK) cells.
View Article and Find Full Text PDFThe opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysis.
Pharmacol Res
May 2024
Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Electronic address:
There are multiple disease-modifying immunotherapies showing the potential of preventing or delaying the progression of type 1 diabetes (T1D). We designed and performed this systematic review and meta-analysis to gain an overview of what a role immunotherapy plays in the treatment of T1D. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to December 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!